Obtains patent on Biomarker to predict the risk of getting nerve damage during cancer treatment with chemotherapy

VibroSense Dynamics AB (“VibroSense”) has received an Intention to Grant from the European Patent Office (EPO) regarding a patent on a Biomarker to predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy.

The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer.
The patent covers both the device and the method and strengthens the company's IP (Intellectual Property) protection. In addition to patents, VibroSense Dynamics' products are protected by encrypted algorithms in the software of the VibroSense Meter® II instrument.

"It is well known that the nervous system is affected by chemotherapy, with a high risk of having permanent nerve damage. Many treatments also have to be discontinued in advance as a result of the nerve damage becoming too severe. With our new discovery, we can help doctors and nurses to identify people with an increased risk of nerve damage at an early stage. This makes it possible to make the treatment more individualized," says Toni Speidel, CTO at VibroSense Dynamics AB.

About CIPN
CIPN is a nerve injury that occurs as a side effect of certain chemotherapy drugs. It most often affects sensory nerves in the hands and feet, but can also cause motor and autonomic symptoms. It is one of the most treatment-limiting side effects of cancer therapy. CIPN is a common complication and approximately 20–30% of patients receiving neurotoxic chemotherapy drugs develop chronic nerve injury.

Lung cancer is the most common cancer in both the EU and Asia, especially among men. Smoking is the main risk factor. Breast cancer is the most common cancer in women globally. Incidence is increasing in both the Western world and parts of Asia, especially in urbanized areas. Colorectal cancer is the third most common cancer globally and is increasing in younger age groups, especially in Asia where Western diets are becoming more common. For these three cancers, the incidence is estimated1 to be around 5.6 million new cases per year in the EU and Asia.

1. Source GLOBOCAN, Eurostat, World Cancer Research Fund, RCC Knowledge

Contact
Toni Speidel, CTO VibroSense Dynamics AB
Tel: +46 40 88 026 
Email: info@vibrosense.com
www.vibrosense.com

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers. 

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.

Läs mer på Cision